Gain Therapeutics, Inc. (GANX)

Market Cap	63.27M
Revenue (ttm)	n/a
Net Income (ttm)	-18.59M
Shares Out	35.95M
EPS (ttm)	-0.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	502,532
Open	1.770
Previous Close	1.740
Day's Range	1.720 - 1.820
52-Week Range	1.000 - 3.190
Beta	0.14
Analysts	Strong Buy
Price Target	8.00 (+354.55%)
Earnings Date	Aug 12, 2025

About GANX

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company’s lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson’s...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 18, 2021
• Employees: 25
• Stock Exchange: NASDAQ
• Ticker Symbol: GANX
• Website: https://gaintherapeutics.com

Analyst Summary

According to 4 analysts, the average rating for GANX stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 354.55% from the latest price.

Price Target

$8.0

(354.55% upside)

Analyst Consensus: Strong Buy